Compare · ADXS vs AZRX

ADXS vs AZRX

Side-by-side comparison of Advaxis, Inc. (ADXS) and AzurRx BioPharma, Inc. (AZRX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ADXS and AZRX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
  • AZRX has more recent analyst coverage (1 ratings vs 0 for ADXS).
MetricADXSAZRX
Company
Advaxis, Inc.
AzurRx BioPharma, Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Major Pharmaceuticals
Major Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
n/a
2016
News (4w)
0
0
Recent ratings
0
1
ADXS

Advaxis, Inc.

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

AZRX

AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.

Latest ADXS

Latest AZRX